Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: telmisartan

« Back to Dashboard
Telmisartan is the generic ingredient in two branded drugs marketed by Boehringer Ingelheim, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma Ltd, Glenmark Generics, Inventia Hlthcare, Mylan Pharms Inc, Sandoz Inc, Torrent Pharms Ltd, Watson Labs, and Zydus Pharms Usa Inc, and is included in eleven NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has seventy-seven patent family members in thirty-seven countries.

There are thirty-six drug master file entries for telmisartan. Four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: telmisartan

Drug Master File Entries: see list36
Suppliers / Packaging: see list13
Therapeutic Class:Cardiovascular Agents

Pharmacology for Ingredient: telmisartan

Tentative approvals for TELMISARTAN

Applicant Application No. Form Dosage
<disabled><disabled>TABLET; ORAL40MG; 12.5MG
<disabled><disabled>TABLET; ORAL80MG; 12.5MG
<disabled><disabled>TABLET; ORAL80MG; 25MG

Clinical Trials for: telmisartan

CKD-828 Drug Interaction Study (Telmisartan)
Status: Completed Condition: Healthy Male Volunteers

Use of Telmisartan and Captopril in Inflammation of Hemodialysis Patients
Status: Completed Condition: Inflammation; End-stage Renal Disease

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)
Status: Completed Condition: Hypertension; Hyperlipidemia

Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
Status: Completed Condition: Essential Hypertension; Hyperlipidemia

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
Status: Completed Condition: Hypertension

Telmisartan, Amlodipine and Combination in Healthy Subjects
Status: Completed Condition: Healthy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd
TABLET;ORAL206511-003Sep 3, 2015RXNo<disabled><disabled>
Sandoz Inc
TABLET;ORAL203867-003Nov 3, 2014RXNo<disabled><disabled>
Glenmark Generics
TABLET;ORAL090032-002Jul 7, 2014RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: telmisartan

Country Document Number Publication Date
Hungary0105148Jan 28, 2003
European Patent Office1144386Oct 17, 2001
European Patent Office1498124Jul 04, 2007
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn